D. Boral Capital Reaffirms Buy Rating for Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reiterated by equities research analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They currently have a $36.00 price objective on the biopharmaceutical company’s stock. D. Boral Capital’s price target suggests a potential upside of 292.16% from the company’s current price.

Other analysts also recently issued research reports about the stock. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Omeros in a research report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Omeros in a report on Thursday, November 14th. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Down 4.5 %

OMER stock opened at $9.18 on Thursday. The business has a 50 day moving average price of $9.27 and a 200 day moving average price of $6.71. The stock has a market cap of $531.98 million, a price-to-earnings ratio of -3.97 and a beta of 1.98. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60.

Institutional Investors Weigh In On Omeros

Several hedge funds have recently made changes to their positions in the business. Two Sigma Investments LP increased its position in Omeros by 8.8% in the 4th quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company’s stock valued at $1,610,000 after acquiring an additional 13,201 shares during the period. ProShare Advisors LLC increased its holdings in shares of Omeros by 75.0% in the fourth quarter. ProShare Advisors LLC now owns 18,496 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 7,927 shares during the period. Nomura Holdings Inc. increased its holdings in shares of Omeros by 136.2% in the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company’s stock valued at $7,383,000 after purchasing an additional 430,932 shares during the period. Millennium Management LLC raised its stake in shares of Omeros by 46.2% during the fourth quarter. Millennium Management LLC now owns 85,671 shares of the biopharmaceutical company’s stock worth $846,000 after purchasing an additional 27,088 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Omeros by 3.6% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 1,110 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.